

Global Mantle Cell Lymphoma Drugs and Companies Pipeline Review H2 2016

Mantle Cell Lymphoma Treatment Pipeline Review H2 2016

PUNE, INDIA, September 12, 2016

/EINPresswire.com/ -- Summary

'[Mantle Cell Lymphoma](#) - Pipeline Review, H2 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/636760-mantle-cell-lymphoma-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/636760-mantle-cell-lymphoma-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and



universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/636760-mantle-cell-lymphoma-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Mantle Cell Lymphoma Overview 10

Therapeutics Development 11

Pipeline Products for Mantle Cell Lymphoma - Overview 11

Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 12

Mantle Cell Lymphoma - Therapeutics under Development by Companies 13

Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 17

Mantle Cell Lymphoma - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Mantle Cell Lymphoma - Products under Development by Companies 21

Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 26

Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 27

AB Science SA 27

AbbVie Inc 28

Acetylon Pharmaceuticals, Inc. 29

Actinium Pharmaceuticals, Inc. 30

Affimed GmbH 31

Amgen Inc. 32

Asana BioSciences, LLC 33

Astellas Pharma Inc. 34

Astex Pharmaceuticals, Inc. 35

Bayer AG 36

BeiGene, Ltd. 37

Bristol-Myers Squibb Company 38

Celgene Corporation 39

Cellular Biomedicine Group, Inc. 40

Eisai Co., Ltd. 41

Eli Lilly and Company 42

EpiZyme, Inc. 43

Gilead Sciences, Inc. 44

GlaxoSmithKline Plc 45

Hutchison MediPharma Limited 46

ImmunoGen, Inc. 47

Immunomedics, Inc. 48

Incyte Corporation 49

Inflection Biosciences Limited 50

Johnson & Johnson 51

Juno Therapeutics Inc. 52

Karyopharm Therapeutics, Inc. 53

Kite Pharma, Inc. 54

LFB S.A. 55

MacroGenics, Inc. 56

MedImmune, LLC 57

Merck & Co., Inc. 58

Merck KGaA 59

Millennium Pharmaceuticals Inc 60

MorphoSys AG 61

Nordic Nanovector ASA 62

Novartis AG 63

Onconova Therapeutics, Inc. 64

Oncternal Therapeutics, Inc. 65

Patrys Limited 66

Pharmacyclics, Inc. 67

Portola Pharmaceuticals, Inc. 68

Seattle Genetics, Inc. 69

Selvita S.A. 70

Stemline Therapeutics, Inc. 71

Takeda Pharmaceutical Company Limited 72

TG Therapeutics, Inc. 73

Vivolux AB 74

Mantle Cell Lymphoma - Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77
Assessment by Mechanism of Action 82
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 91
(INCB-039110 + INCB-040093) - Drug Profile 91
13197 - Drug Profile 92
AB-8779 - Drug Profile 94
abexinostat hydrochloride - Drug Profile 95
acalabrutinib - Drug Profile 98
ACY-241 - Drug Profile 101
ACY-775 - Drug Profile 103
AFM-11 - Drug Profile 104
alisertib - Drug Profile 105
AMG-319 - Drug Profile 110
ASN-002 - Drug Profile 112
AT-7519 - Drug Profile 113
avicin d - Drug Profile 116
BC-8Y90 - Drug Profile 117

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636760

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.